Diabetic Gastroparesis Clinical Trial
Official title:
Prevalence Of Gastroparesis In Type2 Diabetic Patients In Assiut University Hospital And Value Of Nuclear Imaging In Diagnosis
Gastroparesis is defined by objective delaying of gastric emptying without any evidence of mechanical obstruction. Diabetic gastroparesis is a potential complication that occurs in the setting of poorly controlled diabetes, resulting from dysfunction in the coordination and function of the autonomic nervous system, neurons, and specialized pacemaker cells (interstitial cells of Cajal, ICC) of the stomach and intestine, and the smooth muscle cells of the gastrointestinal tract
Hyperglycemia (random blood glucose greater than 200 mg/dL), commonly seen in uncontrolled diabetes, has been associated with diabetic gastroparesis resulting from neuropathy in the setting of chronic hyperglycemia and does not resolve with improved glycemic control. Acute hyperglycemia, on the other hand, though it can also result in delayed gastric emptying, is often reversible with improved glycemic control. Although there is a stronger association between type 1 diabetes and gastroparesis, the incidence of type 2 diabetes is much greater, and therefore, gastroparesis associated with type 2 diabetes is seen more frequently. Additionally, incretin mimetics are used to treat patients with type 2 diabetes, and these medications pose an additional risk factor for developing gastroparesis.Gastric emptying scintigraphy (GES) is the investigation of choice for evaluating the disorders of gastric emptying because it is a simple, physiological, and sensitive investigation to objectively assess gastric emptying. Standard imaging is performed at 0,1,2,4 hours postprandially. A four-hour study is more sensitive and accurate in diagnosing gastroparesis, and clinicians should avoid shortened 2- and 3-hour studies. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01557296 -
Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis
|
Phase 2 | |
Withdrawn |
NCT03376399 -
Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms
|
||
Completed |
NCT02289846 -
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
|
Phase 2 | |
Not yet recruiting |
NCT02264587 -
Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis
|
Phase 4 | |
Completed |
NCT03544229 -
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
|
Phase 2 | |
Recruiting |
NCT04706832 -
Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study
|
N/A | |
Enrolling by invitation |
NCT05812339 -
Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
|
||
Completed |
NCT02732821 -
G-POEM for Treatment of Refractory Gastroparesis
|
||
Completed |
NCT01030341 -
Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis
|
N/A | |
Recruiting |
NCT05832151 -
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT02025725 -
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
|
Phase 3 | |
Completed |
NCT01916460 -
Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients
|
N/A | |
Completed |
NCT01469286 -
Transcutaneous Electroacupuncture for Gastroparesis
|
Phase 1 | |
Terminated |
NCT00874133 -
The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis
|
N/A | |
Completed |
NCT01126034 -
Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention
|
N/A | |
Recruiting |
NCT05273788 -
Thoracic Neuromodulation for Diabetic Gastroparesis
|
N/A | |
Suspended |
NCT00470795 -
Acupuncture for Diabetic Gastroparesis
|
Phase 3 | |
Completed |
NCT00139893 -
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
|
N/A | |
Recruiting |
NCT04254549 -
Rifaximin in Patients With Diabetic Gastroparesis
|
Phase 2 | |
Not yet recruiting |
NCT04661215 -
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
|